$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

Stock Information for RenovoRx Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About RenovoRx Inc.

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
RenovoRx To Announce Promising New Clinical Data Using its TAMP(TM) Therapy Platform in an Abstract to be Presented at ASCO GI 2026
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.